Avalon’s Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction
July 31 2024 - 8:00AM
Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ:
ALBT), a developer of innovative cell-based technology,
cellular therapy and precision diagnostics, today announced that
Laboratory Services MSO, LLC (“LSM”) has launched a
direct-to-consumer and non-invasive DNA test in the U.S. that tests
for potential predisposition to opioid dependence. To purchase or
find out more information, please visit www.dna4addiction.com.
Avalon owns a 40% equity interest in LSM.
The opioid abuse epidemic continues to devastate
communities across America, representing a significant public
health crisis. According to the Centers for Disease Control and
Prevention (CDC), the United States has experienced a dramatic rise
in drug overdose deaths. In 2022, opioids were involved in over 75%
of the nearly 107,000 drug overdose fatalities. From 2020 to 2021
alone, opioid-involved death rates increased by more than 15%,
while synthetic opioid death rates increased by over 22%.
DNA4Addiction offers a convenient home testing
kit for customers to collect a DNA sample and send it for analysis.
Researchers have identified 15 genetic markers linked to opioid
dependence. These markers influence susceptibility to developing
opioid dependence through factors such as neurotransmitter
activity, reward pathways, and substance sensitivity. The test
analyzes these markers to assess genetic predisposition to opioid
dependence. For example, variations in neurotransmitter function,
like dopamine, can affect the brain’s reward system and related
behaviors. The results categorize individuals into High Risk,
Moderate Risk, or Reduced Risk levels based on specific genetic
variations. While this test is not a diagnosis, it provides
valuable insights for proactive health management.
"Having a genetic predisposition to opioid
dependence can significantly impact an individual’s susceptibility
to excessive opioid use," stated David Jin, M.D., Ph.D., President
and Chief Executive Officer of Avalon GloboCare. "Though it is not
a diagnosis or guarantee, genetic factors play a crucial role in
shaping one’s response to opioids, influencing tolerance, drug
reaction, and the likelihood of developing dependence. Recognizing
this predisposition is essential for early intervention and
prevention efforts. LSM has developed the DNA4Addiction testing kit
to provide insights into an individual’s genetic predisposition to
opioid addiction. Results from this kit can empower people to make
informed decisions about their health and well-being. With this
knowledge, individuals can take proactive steps to mitigate risk
and seek appropriate support and resources."
Bob Forrest, Cofounder of Oro House Recovery Center and Brand
Ambassador for DNA4Addiction, commented, “The opioid addiction
crisis continues to escalate, making proactive measures more
crucial than ever. DNA4Addiction equips individuals, especially
parents, with the tools to understand addiction risks from a
genetic perspective. This knowledge can guide necessary lifestyle
changes and precautions to prevent falling victim to the addiction
crisis. DNA4Addiction represents a significant advancement in
overall wellness and combating addiction. Parents now have an
invaluable resource to help protect their children. Given the
prevalent use of opiates for pain management today, the importance
and value of DNA4Addiction cannot be overstated.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a
commercial stage company dedicated to developing and delivering
innovative, transformative, precision diagnostics and clinical
laboratory services. Avalon is working to establish a leading role
in the innovation of diagnostic testing, utilizing proprietary
technology to deliver precise, genetics-driven results. The Company
also provides laboratory services, offering a broad portfolio of
diagnostic tests, including drug testing, toxicology, and a broad
array of test services, from general bloodwork to anatomic
pathology, and urine toxicology. For more information about Avalon
GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare’s
developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press
release are “forward-looking statements” within the meaning of the
federal securities laws. Forward-looking statements are made based
on our expectations and beliefs concerning future events impacting
the Company and therefore involve several risks and uncertainties.
You can identify these statements by the fact that they use words
such as “will”, “anticipate”, “estimate”, “expect”, “should”,
“may”, and other words and terms of similar meaning or use of
future dates, however, the absence of these words or similar
expressions does not mean that a statement is not forward-looking.
Forward-looking statements provide current expectations of future
events based on certain assumptions and include any statement that
does not directly relate to any historical or current fact,
including statements regarding the ability to enter into a
definitive agreement, as well as the Company’s commercialization,
distribution and sales of its products and the ability to compete
with other similar products. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors as disclosed in our filings with the
Securities and Exchange Commission located at their website
(http://www.sec.gov), including our Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, and Form 8-Ks filed or furnished
with the SEC. In addition to these factors, actual future
performance, outcomes, and results may differ materially because of
more general factors including (without limitation) general
industry and market conditions and growth rates, economic
conditions, and governmental and public policy changes. The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the
date of the press release.
Contact Information: Avalon GloboCare Corp.4400
Route 9, Suite 3100Freehold, NJ 07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo Communications, LLCTel: (212)
671-1020 Ext. 304albt@crescendo-ir.com
Avalon GloboCare (NASDAQ:ALBT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Avalon GloboCare (NASDAQ:ALBT)
Historical Stock Chart
From Oct 2023 to Oct 2024